ELAN PHARMACEUTICAL INVESTMENTS LTD 4
4 · DOV PHARMACEUTICAL INC · Filed Apr 28, 2004
Insider Transaction Report
Form 4
ELAN CORP PLC
10% Owner
Transactions
- Sale
Common Stock
2004-04-27$19.51/sh−200$3,902→ 711,020 total(indirect: I) - Sale
Common Stock
2004-04-27$19.30/sh−5,000$96,500→ 617,620 total(indirect: I) - Sale
Common Stock
2004-04-27$19.35/sh−46,800$905,580→ 659,520 total(indirect: I) - Exercise of In-Money
Common Stock
2004-04-26$10.00/sh+36,479$364,790→ 711,220 total(indirect: I) - Sale
Common Stock
2004-04-27$19.30/sh−5,800$111,961→ 622,620 total(indirect: I) - Exercise of In-Money
Warrants (right to buy)
2004-04-26−75,000→ 0 total(indirect: I)Exercise: $10.00From: 2003-03-24Exp: 2006-01-21→ Common Stock (36,479 underlying) - Sale
Common Stock
2004-04-27$19.40/sh−4,500$87,300→ 706,520 total(indirect: I) - Sale
Common Stock
2004-04-27$19.20/sh−480,921$9,233,683→ 136,699 total(indirect: I) - Exercise of In-Money
Warrants (right to buy)
2004-04-26−121,500→ 0 total(indirect: I)Exercise: $3.41From: 1999-01-21Exp: 2005-01-15→ Common Stock (100,220 underlying) - Sale
Common Stock
2004-04-27$19.32/sh−30,900$597,143→ 628,420 total(indirect: I) - Exercise of In-Money
Common Stock
2004-04-26$3.41/sh+100,220$341,750→ 674,741 total(indirect: I)
Footnotes (4)
- [F1]These securities were beneficially owned indirectly by Elan Corporation, plc ("Elan") and by its direct wholly-owned subsidiary, Elan International Services, Ltd. ("EIS"), and directly by Elan Pharmaceutical Investments, Ltd., a wholly-owned subsidiary of Elan and EIS.
- [F2]These securities were beneficially owned indirectly by Elan Corporation, plc and directly by its direct wholly-owned subsidiary, Elan International Services, Ltd.
- [F3]The warrant was exercisable for 121,500 shares of common stock at an exercise price of $3.41 but was exercised in a cashless transaction for 100,220 shares of common stock.
- [F4]The warrant was exercisable for 75,000 shares of common stock at an exercise price of $10.00 but was exercised in a cashless transaction for 36,479 shares of common stock.